A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first‐line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin
Open Access
- 25 April 2020
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 126 (2), 292-299
- https://doi.org/10.1111/bju.15096
Abstract
Objectives To assess the efficacy and tolerability of the dual EGFR/VEGFR inhibitor, vandetanib, in combination with carboplatin and gemcitabine in the first line treatment of patients with advanced urolthelial cancer (UC) who were unsuitable for cisplatin. Patients and methods From 2011 and 2014, 82 patients were randomised from 16 hospitals across the UK into the TOUCAN double‐blind, placebo‐controlled randomised phase II receiving six 21‐day cycles of intravenous carboplatin (AUC 4.5 day 1) and gemcitabine (1000mg/m2 days 1,8) in combination with either oral vandetanib 100mg or placebo (once daily). Progression‐free survival (PFS – primary endpoint), adverse events (AEs), tolerability and feasibility of use, objective response rate and overall survival (OS) were evaluated. Intention‐to‐treat and per protocol analyses were used to analyse the primary endpoint. Results Eighty‐two patients were randomised 1:1 to vandetanib (n=40) or placebo (n=42). 25 patients (30%) completed 6 cycles of all allocated treatment. Toxicity ≥grade 3 was experienced in 80% (n=32) and 76% (n=32) of patients on vandetanib and placebo arms respectively. Median PFS was 6.8 and 8.8 months for vandetanib and placebo arms, respectively (HR=1.07, 95% CI 0.65‐1.76, p=0.71); median OS was 10.8 vs 13.8 months (HR=1.41, 95% CI 0.79‐2.52, p=0.88); and radiological response rates were 50% and 55%. Conclusion There is no evidence that vandetanib improves clinical outcome in this setting. Our data do not support its adoption as the regimen of choice for first line treatment in UC patients who were unfit for cisplatin.Keywords
Funding Information
- Cancer Research UK (CRUKE/09/024)
This publication has 25 references indexed in Scilit:
- Comprehensive molecular characterization of urothelial bladder carcinomaNature, 2014
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986Journal of Clinical Oncology, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: Dose dependency and modulation of biomarkersOncology Reports, 2011
- VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cellsOncology Reports, 2010
- Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trialThe Lancet Oncology, 2010
- Expression and Significance of Vascular Endothelial Growth Factor Receptor 2 in Bladder CancerJournal of Urology, 2006
- Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology GroupUrology, 2004
- VEGF receptor expression and signaling in human bladder tumorsOncogene, 2003
- A feasibility study of carboplatin with fixed dose of gemcitabine in ‘unfit’ patients with advanced bladder cancerEuropean Journal of Cancer, 2001